Wednesday 12th March 2025 - Friday 14th March 2025
We had an incredible time at NextGen Biomed 2025, where industry leaders gathered to explore the latest advancements in biopharmaceuticals. Peptides, oligonucleotides, and ADCs were at the forefront of industry discussions, reflecting their growing importance in therapeutic development. As these molecules become more complex, so do the analytical challenges associated with their characterization, requiring advanced solutions to ensure structural integrity, purity, and efficacy.
Key Focus Areas:
At BioPharmaSpec, we leverage decades of expertise in biopharmaceutical characterization to support successful development from discovery to regulatory submission.
On Day 2 of NextGen Biomed 2025, Dr. Richard L. Easton, our Technical Director of Structural Analysis, shared key insights in his presentation:
“Application of Varied Mass Spectrometry Techniques to Synthetic Peptide Characterization.”
Dr. Easton explained that while chemical synthesis of peptides allows precise molecular design, including stability-enhancing modifications, it also introduces analytical challenges. With EMA and FDA regulations demanding detailed structural characterization, he highlighted the power of LC-MS in sequencing, impurity profiling, and modification assessment. His talk demonstrated how mass spectrometry detects critical impurities—such as truncations and stereoisomeric variations—ensuring both regulatory compliance and drug safety.
His presentation reinforced BioPharmaSpec’s leadership in peptide analysis, showcasing our expertise in structural elucidation and our ability to support biopharmaceutical developers with cutting-edge analytical solutions.
Talk to our scientists today about how you can access BioPharmaSpec's technical expertise and range of instrumentation at a lab near you!
